{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118801","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.129987+00:00","generated_at":"2026-06-08T02:34:01.500718+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elutia closes Orthobiologics sale to Berkeley Biologics for ~$14.6M cash plus up to $20M earn-out","bullets":["Sale completed Nov 8, 2023; initial cash payment of ~$14.6M after customary adjustments.","Eligible for earn-out payments of 10% of annual revenue (capped at $20M) over 5 years.","Repaid $2.0M of SWK credit facility at closing; additional $2.0M due by Feb 15, 2024.","Entered 2-year manufacturing agreement with Berkeley for SimpliDerm product.","Pro forma continuing ops: net loss $26.0M for 9mo 2023 (discontinued ops removed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118801","json":"https://secwatch.observer/filing/0001104659-23-118801.json","markdown":"https://secwatch.observer/filing/0001104659-23-118801.md","text":"https://secwatch.observer/filing/0001104659-23-118801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923118801/0001104659-23-118801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923118801/tm2330673d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:34:01.500718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c586502c4ce9e344df0c9dcd25a0322c915835c","claim":"ELUTIA INC. completed a disposition involving Berkeley Biologics, LLC for initial cash payment of approximately $14.6 million, after customary adjustments (closed 2023-11-08).","evidence_excerpt":"dermis products for use in the field of breast reconstruction) (the “Closing”). Shortly after the Closing Date, Elutia received an initial cash payment of approximately $14.6 million, after customary adjustments. In addition, for each of the five years following the Closing, the Company is eligible under the Purchase Agreement to receive an earn-out payment","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923118801/0001104659-23-118801-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Berkeley Biologics, LLC"},{"label":"Consideration","value":"initial cash payment of approximately $14.6 million, after customary adjustments"},{"label":"Closing","value":"2023-11-08"}],"fact_type":"ma_transaction"},{"claim_id":"704a2305af5fcbfb55cd79c2fda0d84a573b5596","claim":"ELUTIA INC. entered into Manufacturing Agreement.","evidence_excerpt":"information required by this Item 1.01 with respect to the Amendment Letter and the Manufacturing Agreement (each as defined below) is set forth in","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923118801/0001104659-23-118801-index.htm","confidence":0.4,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"}],"fact_type":"material_agreement"},{"claim_id":"ab15fc92e6153c38309c8fcd82ee4292c214a2a1","claim":"ELUTIA INC. entered into Amendment Letter.","evidence_excerpt":"information required by this Item 1.01 with respect to the Amendment Letter and the Manufacturing Agreement (each as defined below) is set forth in","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923118801/0001104659-23-118801-index.htm","confidence":0.4,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}